Acadia Pharmaceuticals traded at $14.37 this Friday July 1st, increasing $0.28 or 1.99 percent since the previous trading session. Looking back, over the last four weeks, Acadia Pharmaceuticals gained 11.35 percent. Over the last 12 months, its price fell by 40.86 percent. Looking ahead, we forecast Acadia Pharmaceuticals to be priced at 13.98 by the end of this quarter and at 12.87 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
14.37
Daily Change
1.99%
Yearly
-40.86%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 5,825.00 134.00 2.35% -44.52%
Acadia Pharmaceuticals 14.37 0.28 1.99% -40.86%
ALKERMES 30.53 0.74 2.48% 20.67%
Alnylam Pharmaceuticals 148.25 2.40 1.65% -13.52%
Aptinyx Inc 0.55 -0.01 -1.42% -80.50%
Biogen 210.63 6.69 3.28% -39.60%
BioMarin Pharmaceutical 84.98 2.11 2.55% -0.57%
Bristol-Myers Squibb 76.84 -0.16 -0.21% 14.77%
Cara Therapeutics 8.62 -0.51 -5.59% -40.06%
Corcept Therapeutics 25.44 1.66 6.98% 14.03%
Cytokinetics 41.00 1.71 4.35% 98.93%
Intercept Pharmaceuticals 14.13 0.32 2.32% -29.31%
Incyte Corp 77.67 1.70 2.24% -7.07%
Intra Cellular Therapies 55.17 -1.91 -3.35% 30.58%
J&J 179.52 2.01 1.13% 6.24%
Eli Lilly 324.71 0.48 0.15% 38.79%
Moderna Inc 149.95 7.10 4.97% -36.00%
Marinus Pharmaceuticals 4.76 -0.08 -1.65% -74.73%
Neurocrine Biosciences 99.25 1.77 1.82% 0.65%
Pfizer 52.31 -0.12 -0.23% 31.66%
Prothena 27.89 0.74 2.73% -49.72%
PTC Therapeutics 41.85 1.79 4.47% -2.88%
Ultragenyx Pharmaceutical 62.65 2.99 5.01% -33.50%
Seattle Genetics 180.11 3.17 1.79% 14.52%
Sarepta Therapeutics 75.71 0.75 1.00% 0.62%
Vanda Pharmaceuticals 11.19 0.29 2.66% -46.25%
Vertex Pharmaceuticals 287.32 5.53 1.96% 43.27%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%

Acadia Pharmaceuticals
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).